265 related articles for article (PubMed ID: 17154260)
21. Addition of cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation.
Xu H; Chilton PM; Huang Y; Schanie CL; Yan J; Ildstad ST
Transplantation; 2007 Apr; 83(7):954-63. PubMed ID: 17460568
[TBL] [Abstract][Full Text] [Related]
22. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
23. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
24. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.
Hofmann M; Brinkmann V; Zerwes HG
Int Immunopharmacol; 2006 Dec; 6(13-14):1902-10. PubMed ID: 17161343
[TBL] [Abstract][Full Text] [Related]
25. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
26. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation.
Teshima T; Liu C; Lowler KP; Dranoff G; Ferrara JL
Cancer Res; 2002 Feb; 62(3):796-800. PubMed ID: 11830535
[TBL] [Abstract][Full Text] [Related]
27. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
Maeda Y; Seki N; Sato N; Sugahara K; Chiba K
Int Immunol; 2010 Jun; 22(6):515-25. PubMed ID: 20497959
[TBL] [Abstract][Full Text] [Related]
28. Adoptive transfer of small numbers of DX5+ cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation: a potential role for NKT lymphocytes.
Margalit M; Ilan Y; Ohana M; Safadi R; Alper R; Sherman Y; Doviner V; Rabbani E; Engelhardt D; Nagler A
Bone Marrow Transplant; 2005 Jan; 35(2):191-7. PubMed ID: 15558045
[TBL] [Abstract][Full Text] [Related]
29. Rejection following donor or recipient preoperative treatment with FTY720 in rat small bowel transplantation.
Sakagawa T; Kiyochi H; Honda K; Kobayashi N
Transpl Immunol; 2004 Nov; 13(3):161-8. PubMed ID: 15381198
[TBL] [Abstract][Full Text] [Related]
30. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
[TBL] [Abstract][Full Text] [Related]
31. Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host.
Hummel S; Wilms D; Vitacolonna M; Zöller M
J Leukoc Biol; 2002 Nov; 72(5):898-912. PubMed ID: 12429711
[TBL] [Abstract][Full Text] [Related]
32. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
Pachnio A; Dietrich S; Klapper W; Humpe A; Schwake M; Sedlacek R; Gramatzki M; Beck C
Bone Marrow Transplant; 2006 Jul; 38(2):157-67. PubMed ID: 16820783
[TBL] [Abstract][Full Text] [Related]
33. IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy.
Yarkoni S; Prigozhina TB; Slavin S; Askenasy N
Biol Blood Marrow Transplant; 2012 Apr; 18(4):523-35. PubMed ID: 22227590
[TBL] [Abstract][Full Text] [Related]
34. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
[TBL] [Abstract][Full Text] [Related]
35. FTY720 reduces T-cell recruitment into murine intestinal allograft and prevents activation of graft-infiltrating cells.
Kimura T; Hasegawa T; Nakai H; Azuma T; Usui N; Sasaki T; Okada A
Transplantation; 2003 May; 75(9):1469-74. PubMed ID: 12792499
[TBL] [Abstract][Full Text] [Related]
36. FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis.
Fujii R; Kanai T; Nemoto Y; Makita S; Oshima S; Okamoto R; Tsuchiya K; Totsuka T; Watanabe M
Am J Physiol Gastrointest Liver Physiol; 2006 Aug; 291(2):G267-74. PubMed ID: 16574986
[TBL] [Abstract][Full Text] [Related]
37. Allorecognition and graft-versus-host disease.
Theobald M
Bone Marrow Transplant; 1995 Apr; 15(4):489-98. PubMed ID: 7655371
[TBL] [Abstract][Full Text] [Related]
38. [Study the mechanisms and inducing transplantation immune tolerance of FTY720].
Zhang L; Zhu T; Sun EW; Shen SQ; Guo H; Min ZL; Chen ZH
Zhonghua Wai Ke Za Zhi; 2003 Oct; 41(10):773-7. PubMed ID: 14766054
[TBL] [Abstract][Full Text] [Related]
39. Evidence that FTY720 induces rat thymocyte apoptosis.
Isoyama N; Takai K; Tsuchida M; Matsumura M; Naito K
Transpl Immunol; 2006 Apr; 15(4):265-71. PubMed ID: 16635748
[TBL] [Abstract][Full Text] [Related]
40. Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease.
Ewing P; Miklos S; Olkiewicz KM; Müller G; Andreesen R; Holler E; Cooke KR; Hildebrandt GC
Exp Hematol; 2007 Jan; 35(1):155-63. PubMed ID: 17198884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
